Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line treatment for non-small cell lung cancer (NSCLC) with ...

Earendil Labs has raised an impressive $787 million in financing for its AI-powered drug discovery and development platform, ...

After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

As the FDA released its draft guidance, the NIH said it will invest $150 million in human-based research to develop the tools ...

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new ...

First developed in the 1960s, they are supported by extensive clinical evidence and recommended by leading professional ...

Ask a pharma commercial team where lung cancer patients are treated in France and most will point to major academic centres ...

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey, and this year’s theme is “Industrializing Intelligence: The ...

This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity, a rare condition in which ...